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Non-alcoholic fatty liver disease (NAFLD) is common in patients with growth hormone
deficiency (GHD). Some noninvasive techniques have been used to quantify liver fat,
such as the controlled attenuation parameter (CAP).
Objective: To evaluate CAP as a tool to identify liver steatosis and its relationship with
different clinical and biochemical metabolic parameters in a group of patients with severe
adult growth hormone deficiency (AGHD), and to compare the evolution of metabolic
profiles after 6 months of human growth hormone (rhGH) replacement therapy in a
subgroup of patients.
Methods: Cross-sectional observational study at baseline of naive rhGH multiple
pituitary hormonal deficiency (MPHD) hypopituitarism patients. A 6-month intervention
clinical trial in a selected group of a non-randomized, non-controlled cohort was
also applied.
Results: Liver stiffness measurement (LSM) was normal in severe AGHD patients. CAP
evaluation showed steatosis in 36.3% of baseline patients (8/22), associated with higher
BMI, waist circumference, insulin, and alanine aminotransferase (ALT) levels. According to
steatosis degree by CAP, child-onset growth hormone deficiency (CO-GHD) was graded
as 68.75% (11/16) S0, 12.5% (2/16) S1, and 18.75% (3/16) S3, whereas AO-GHD was
graded as 50% (3/6) S0, 16.66% (1/6) S2, and 33.33% S3. After 6 months of hrGH
replacement, CAP measurements did not change significantly, neither on group without
hepatic steatosis at baseline (194.4 ± 24.3 vs. 215.4 ± 51.3; p = 0.267) nor on the
group with hepatic steatosis (297.2 ± 32.3 vs. 276.4 ± 27.8; p = 0.082). A significant
improvement of body composition was observed only in the first group.
Conclusions: We have demonstrated the importance of CAP as a non-invasive tool
in the liver steatosis identification on hypopituitary patients. This method may be an
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important indicator of the severity of metabolic disorders in MPHD patients. In our study,
no liver health modification in LSM at baseline or after 6 months of rhGH replacement
was found. Longer studies can help to establish the potential repercussions of growth
hormone replacement therapy on liver steatosis.
Keywords: transient elastography, controlled atenuation parameter, liver steatosis, metabolic syndrome, adult
growth hormone deficiency (AGHD)
INTRODUCTION
Significant metabolic changes are observed in AGHD, such as
negative effects on lipoprotein metabolism, lean mass reduction,
fat mass increase, and intra-abdominal fat, leading to an
increased risk of cardiovascular events (1–3). Central obesity
and altered lipid profiles give rise to the development of
Metabolic Syndrome (MetS), which has insulin resistance as a key
pathogenic mechanism (4).
NAFLD is used to define the accumulation of liver fat in
a patient without a prior history of alcohol abuse. The higher
concentration of lipids, especially triglycerides in hepatocytes,
leads to the development of hepatic steatosis, defined as the
accumulation of fatty tissue higher than 5% of liver weight (5, 6).
Hepatic steatosis is considered a reversible change but may
progress to an inflammatory process (steatohepatitis) and to
liver cirrhosis. In this case, it may lead to a higher risk of
hepatocarcinoma (7, 8). In addition, NAFLD represents an
isolated cardiovascular risk factor and is associated with an
increased incidence of cardiovascular disease (9).
The high prevalence of hepatic steatosis on AGHD patients,
confirmed by liver biopsy, reveals the presence of an increased
risk of progression to non-alcoholic steatohepatitis (NASH) (10).
Therefore, the GHD in the subgroup of patients with MPHD
represents a high risk of NAFLD and progression to NASH and
cirrhosis (7, 11).
An important non-invasive technique has been used in the
hepatology field to identify liver fibrosis—FibroScan R© Echosens
(12). Transient elastography (TE) by FibroScan R© has been
widely used in the last decade as a fast, non-invasive, and
reproducible method to evaluate the liver stiffness measurement
(LSM) as a measure of the degree of liver fibrosis. TE measures
low frequency (50Hz) elastic shear wave velocity propagation
through the liver. In this case, shear wave velocity is directly
related to tissue stiffness, which is expressed in kiloPascals (kPa).
Usual tissue stiffness ranges from 2.5 to 7.5 kPa. A normal
values for healthy liver stiffness is estimated to be about 5.5
kPa (13, 14). An available tool in FibroScan R©, validated on
patients with chronic liver disease frommany causes, has enabled
the evaluation of hepatic steatosis using controlled attenuation
parameter (CAP). This parameter is useful for estimating the
attenuation of the propagation of ultrasonic waves signals
through the liver, acquired simultaneously with LSM by the
FibroScan R© probe. CAP is measured in decibels per meter
(dB/m), with typical values ranging from 100 to 400 dB/m. CAP
analysis is effective in the diagnosis and quantification of hepatic
steatosis, from absolute cut-off points, with 90% sensitivity
(15–18). Recent studies have shown that transient elastography
has the best performance on the diagnosis and exclusion of
advanced hepatic fibrosis in NAFLD (19). There is no previous
literature report on the use of Transient Elastography to identify
liver disease on MPHD hypopituitary patients.
OBJECTIVES
The aim of this study is to evaluate the relationship of CAP
with different clinical and biochemical metabolic parameters in
a group of patients with severe AGHD. A secondary objective is
to compare the evolution of metabolic profiles after 6 months of




This is a cross-sectional observational study at baseline of
naive rhGH MPHD hypopituitarism patients and a 6-month
intervention clinical trial in a selected group of a non-
randomized, non-controlled cohort. Data were gathered and
individuals were recruited from October 2016 thru October 2018
at the Endocrinology Unit of University Hospital of Brasilia,
and at the Endocrinology Unit of Instituto Hospital de Base in
Brasilia, located in the Federal District of Brazil.
Twenty-two patients were recruited at baseline and thirteen
of them were enrolled in the intervention subgroup. From the
intervention subgroup, patients who survived malignancies and
those patients who did not agree to continue the study, were
excluded from the group.
The study complied with the WMA Declaration of Helsinki
and its amended versions on ethical principles for medical
research involving human subjects and was approved by
the Ethical Committee on Human Subject Research from
the Fundação de Ensino e Pesquisa em Ciências da Saúde
(FEPECS). All patients signed a proper informed consent before
participating in the study.
Inclusion Criteria
Patients included in the study were adults, with periodical
ambulatory follow-ups, presenting at least one of the following
criteria: (i) confirmed MPHD diagnosis; (ii) GHD initiated and
treated in infancy or with disability developed in adulthood,
for at least 5 years without rhGH replacement. GH deficiency
was defined by GH peak < 3 ng/dl in the insulin tolerance test
and IGF-I concentration <-2SD. Patients with hypopituitarism
secondary to treatment of functioning pituitary tumors
Frontiers in Endocrinology | www.frontiersin.org 2 June 2019 | Volume 10 | Article 364
Carvalho-Furtado et al. CAP and Steatosis in AGHD
(Cushing’s disease, prolactinoma, acromegaly); and chronic use
of supraphysiological doses of corticoids were also excluded.
Evaluation at Baseline
Variables considered were age, gender, signs, and symptoms at
diagnosis. Also considered were comorbidities, anthropometric
measurements, metabolic parameters (glucose, insulin, HOMA
index, glycated hemoglobin, lipid metabolism, TGO, TGP,
GGT) body composition by DXA, and hepatic evaluation by
Fibroscan R© with LSM and CAP measurement. All assessments
were performed after night fasting.
Laboratory Analysis
Serum GH levels were measured by a two-site chemiluminescent
immunometric assay (Immulite, 2000). Assay sensitivity was
0.01 ng/ml and the interassay coefficient of variation was
<10%. Serum IGF-I was measured by a solid-phase enzyme
labeled chemiluminescent immunometric assay with sample
pretreatment on an onboard dilution step (Immulite, 2000). The
manufacturer’s normal range for age and gender was considered.
Inter-assay coefficients of variation were <5%. Peptides were
determined by chemiluminescent methods. Glucose, lipids, and
transaminases were determined respectively by hexokinase and
by IFCC without pyridoxal phosphate.
TABLE 1 | Clinical aspects of baseline adult GHD patients.

























aNon Functioning Pituitary Adenoma
bTraumatic Brain Injury
c1- Sheehan Syndrome, 1-Hipoxic-ischaemic encephalopathy neonatal syndrome, 1-
Meduloblastoma, 1-Dysgerminoma, 1-Astrocytoma, 1-Empty Sela, 1-Histiocytose
Body Composition by Dual Emission X-ray
Absorptiometry (DEXA)
Body composition [including percent of fat body mass (FBM),
truncal fat mass (TFM), lean body mass (LBM), and waist/hip
ratio] was assessed by dual-emission X-ray absorptiometry
(DXA, GE Healthcare, Lunar DPX NT, Diegem, Belgium) with
participants in supine position (20).
FibroScan® Echosens, Paris, France
Transition Elastography (TE) was performed by a trained
operator on the right lobe of the liver through the intercostal
spaces with the patient lying in the dorsal decubitus position and
with the right arm inmaximal abduction. Ultrasound attenuation
(CAP) was only calculated when the liver stiffness measurement
(LSM) was valid in order to ensure an accurate attenuation. A
reliable LSM was defined using the following 3 criteria: (i) at least
10 valid shots; (ii) a success rate (SR: the ratio of valid shots to the
total number of shots) of at least 60%; and (iii) an interquartile
range (IQR) of <30% of the median LSM (IQR/M\30%). The
median value of 10 successful measurements was selected as the
representative value. TE results were expressed as kilopascals
(kPa) for LSM and as dB/m for CAP. LSM ranges from 2.5 to
7.5 kPa, and a healthy liver normal value is estimated to be 5.5
kPa (14, 21). The intensity of hepatic steatosis is graded by CAP
according to published cut-offs bounds (for the M probe S0 <
248; S1= 248–267; S2= 268–279; S3 ≥ 280 dB/m) (17).
TABLE 2 | Metabolic characteristics of baseline GHD patients according to
deficiency onset phase.
Adult Onset Child Onset P-value
(n = 6) (n = 16)
Age (year) 44.13 ± 9.5 27.65 ± 8.0 0.000
BMI (kg/m²) 28.6 ± 3.5 23.2 ± 4.7 0.011
WC (cm) 98.7 ± 9.8 85.0 ± 12 0.021
LBM (%) 58.0 ± 7.9 58.6 ± 8.9 0.867
FBM (%) 39.3 ± 6.8 35.8 ± 8.9 0.403
TFM (%) 43.4 ± 5.0 45.4 ± 12 0.341
waist/hip ratio 1.2 ± 0.07 1.0 ± 0.10 0.003
IGF-1 (ng/ml) 70.5 ± 56.0 58.0 ± 48.0 0.494
HOMA IR 2.5 ± 2.3 0.7 ± 1.4 0.027
Glucose (mg/dl) 81.37 ± 8.9 77.8 ± 10.6 0.418
Insulin (µUI/ml) 12.7 ± 11.0 4.9 ± 6.2 0.049
HbA1c (%) 5.4 ± 0.3 4.8 ± 1.0 0.122
Total cholesterol (mg/dl) 185.4 ± 36.5 191.8 ± 48.7 0.743
LDL-cholesterol (mg/dl) 103.7 ± 30.3 112.1 ± 18.9 0.401
HDL-cholesterol (mg/dl) 48.9 ± 11.1 45.9 ± 10.0 0.510
Triglycerides (mg/dl) 134.5 ± 147 99.0 ± 127.5 0.407
LSM (kPa) 4.3 ± 0.9 4.8 ± 1.6 0.476
CAP (dB/m) 255.2 ± 56.1 228.3 ± 65.9 0.388
BMI, body mass index; WC, waist circumference; LBM, lean body mass; FBM, fat
body mass; TFM, truncal fat mass; IGF-1, insulin growth factor type 1; HOMA IR,
insulin resistance index; HbA1c, glycated hemoglobin; LDL, low density lipoprotein;
HDL, high density lipoprotein; LSM, liver stiffness measurement; CAP, controlled
attenuation parameter.
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Intervention Subgroup
Patients in the intervention subgroup started rhGH replacement
therapy at a dose of 0.2 mg/day (0.6UI) for men and 0.3 mg/day
(0.9UI) for women on oral estrogen therapy. They were evaluated
monthly, with a dose increase of 0.1 mg/day rhGH until reaching
IGF-1 concentrations between −1SD and +1SD for sex and age.
After 6 months, with optimal concentrations of IGF-1 reached,
the initial evaluations were repeated. The same radiological and
biochemical parameters were evaluated at baseline and after 6
months of treatment.
The recombinant growth hormone used for treatment was
Hormotrop R©(4IU, Bergamo). Patients with MPHD who had
survived malignancies were excluded from this group.
Statistical Analysis
The Kolmogorov-Smirnov and the Shapiro-Wilk tests were
used to test the normality of the variables. The Pearson
correlation test was used for normal variables, and the Spearman
correlation test was used for non-normal variables. Student’s t-
test was used to analyze the significance of the variables with
normal distribution, being expressed as media and standard
TABLE 3 | Metabolic profile of baseline DGHA patients according to hepatic
steatosis measured by CAP.
Hepatic Steatosis (CAP)
No Yes Valor P
(n = 14) (n = 8)
Age (year) 31.6 ± 12.2 30.9 ± 11.7 0.897
Gender (M/F) 6/8 5/3
Corticotherapy (N/Y) 3/11 2/6
BMI (kg/m²) 21.6 ± 4.3 27.9 ± 3.9 0.003
WC (cm) 83.2 ± 11.2 98.2 ± 9.8 0.005
HOMA IR 0.75 ± 1.4 1.9 ± 1.9 0.110
Insulin (µUI/ml) 4.43 ± 7.1 8.5 ± 8.4 0.042
HbA1c (%) 5.1 ± 0.33 5.0 ± 0.33 0.458
IGF-1 (ng/ml) 52.0 ± 31.0 73.0 ± 61.2 0.330
Total cholesterol (mg/dl) 178.4 ± 22.1 190.0 ± 30.3 0.314
HDL-cholesterol (mg/dl) 48.1 ± 10.3 41.9 ± 12.4 0.218
LDL-cholesterol (mg/dl) 108.6 ± 22.9 100.2 ± 34.3 0.500
Triglycerides (mg/dl) 95.5 ± 80.0 164.5 ± 371.0 0.127
AST (U/L) 21.0 ± 8.0 24.0 ± 34.0 0.868
ALT (U/L) 16.0 ± 10.0 26.0 ± 29.0 0.010
GGT (U/L) 16.5 ± 13.0 45.0 ± 13.0 0.059
LBM (%) 59.3 ± 9.0 56.8 ± 7.8 0.516
FBM (%) 35.6 ± 9.0 39.0 ± 7.3 0.374
TFM (%) 43.0 ± 13.5 44.3 ± 3.9 0.815
waist/hip ratio 1.05 ± 0.10 1.08 ± 0.13 0.536
LSM (kPa) 4.6 ± 1.7 4.8 ± 0.9 0.721
CAP (dB/m) 196.1 ± 32.7 304.9 ± 37.5 0.001
M/F, male/female; N/Y, yes/no; BMI, body mass index; WC, waist circumference; HOMA
IR, insulin resistance index; HbA1c, glycated hemoglobin; IGF-1, insulin growth factor
type 1; HDL, high density lipoprotein; LDL, low density lipoprotein; AST, aspartate
aminotransferase; ALT, alanine aminotransferase; GGT, gamma glutamyltranspeptidase;
LBM: lean body mass; FBM, fat body mass; TFM, truncal fat mass; LSM, liver stiffness
measurement; CAP, controlled attenuation parameter.
deviation. The independent variables HOMA IR, IGF-I, insulin,
triglycerides, truncal fat, ALT, and AST were considered non-
normal and evaluated by the non-parametric Mann-Whitney
test, being expressed as a median and interquartile interval. The
Fisher exact test was used to test the association between two
independent nominal variables.
Data analysis was performed using the independent
variables before and 6 months after treatment with rhGH
and was conducted using the T-test of paired samples for
normal distribution variables and non-parametric tests of two
independent samples for non-normal variables.
RESULTS
Clinical Characteristics at Baseline
At baseline evaluation, the group of 22 patients presented a
similar distribution between gender, and most of the patients had
a diagnosis of GH deficiency in early childhood. Benign tumoral
diseases were the most common etiology for hypopituitarism
(36.4%), but inflammatory and malignant conditions were also
observed. Half of the patients were submitted to a neurosurgical
procedure. Six patients (27% of total) underwent previous
adjuvant radiotherapy treatment of baseline pathology for more
than 10 years (four patients with craniopharyngioma, one
patient with medulloblastoma, and one patient with suprasellar
dysgerminoma). ACTH deficiency was observed in 77% of
the patients, treated by 5mg of prednisone for more than 1
year (Table 1). From our sample, only one woman, 20 years
old, had a normal gonadotropic axis. All hypogonadic patients
(21/22) were under steroid replacement (estrogen/ progesterone
or testosterone).
Patients who presented adult-onset growth hormone
deficiency (AO-GHD) had higher BMI, waist circumference,
waist/hip ratio, and presented higher HOMA-IR and insulin
FIGURE 1 | patients number according CAP degree.
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FIGURE 2 | Spearman correlation graphics between CAP and metabolic parameters. (A) CAP, controlled attenuation parameter(dB/m) and BMI, body mass index
(kg/m²). (B) CAP and WC, waist circumference (cm). (C) CAP and HOMA IR, homeostatic model assessment insulin resistance. (D) CAP and Insulin (µUI/ml). (E) CAP
and Triglycerides (mg/dl).
levels. Body fat distribution assessed by DXA body composition
did not differ between groups (Table 2).
Hepatic Evaluation by Elastography
Of the 23 patients submitted to FibroScan R©, only one
patient failed the method due to difficulty in acquiring valid
measurements due to narrow intercostal spaces. The patient was
excluded from the study. Considering FibroScan R© results, LSM
has not shown abnormalities or differences on GHD patients
according to the deficiency onset phase, while absolute CAP
values were higher in adult-onset patients but without statistical
significance (Table 2). CAP evaluation showed hepatic steatosis
in 36.3% of the patients (8/22), associated with higher BMI,
waist circumference, insulin, and ALT. Lipid profile and body
composition were not related to fatty liver disease identification
by CAP (Table 3).
According to steatosis degree by CAP, child-onset growth
hormone deficiency (CO-GHD) was graded as 68.75% (11/16)
S0, 12.5% (2/16) S1, and 18.75% (3/16) S3, whereas AO-GHD
was graded as 50% (3/6) S0, 16.66% (1/6) S2, and 33.33%
S3 (Figure 1).
In order to test the relationship between CAP and the
independent variables of metabolic syndrome, the Spearman
correlation was used (Figure 2). Moderately positive correlation
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results were found between CAP measurements with BMI (ρ =
0.621; p = 0.002), WC (ρ = 0.632; p = 0.002), HOMA IR (ρ =
0.447; p= 0.037), insulin (ρ = 0.515; p= 0.014), and triglycerides
(ρ = 0.476; p= 0.025).
Clinical Characteristics of Therapeutic
Intervention Subgroup
Patients in the intervention subgroup started rhGH replacement
therapy at a dose of 0.2 mg/day (0.6UI) for men and 0.3 mg/day
(0.9UI) for women on oral estrogen therapy.
After 6 months of rhGH replacement therapy, the patients
showed significant improvement in body composition, with a
reduction of waist circumference and fat body distribution. A
significant gain of lean body mass and reduction of fat body mass
were also observed, and there was no change in BMI. However,
a significant increase in blood glucose, insulin, and HOMA-
IR index were observed. LSM and CAP measurements did not
change significantly (Table 4).
Intervention subgroup patients were divided according to the
presence of hepatic steatosis measured by CAP, and a statistically
significant improvement on body composition was observed
only in patients without hepatic steatosis after 6 months of
hrGH replacement therapy. CAP measurements did not change
significantly, neither on the group without hepatic steatosis
(194.4 ± 24.3 vs. 215.4 ± 51.3; p = 0.267) nor on the group with
hepatic steatosis (297.2± 32.3 vs. 276.4± 27.8; p= 0.082), during
6 months of follow up. However, worsening absolute values of
glucose, insulin, andHbA1c were found in the group with hepatic
steatosis at baseline, despite the WC reduction (Table 5).
DISCUSSION
Transient elastography by Fibroscan has been used as a fast,
non-invasive, and reproducible method to evaluate liver fibrosis
(13, 14). In addition to accurately evaluating LSM, TE is also
capable of quantifying hepatic steatosis through a physical
parameter (CAP), which is simultaneously acquired with LSM by
the FibroScan probe and which estimates the liver attenuation
levels (17, 18).
CAP is very efficient in detecting even low-grade steatosis,
but neither the presence nor the severity of hepatic steatosis as
measured by CAP predicts liver-related events, cancer, or CVE in
the short period of time (15, 17).
The positive correlation observed between CAP and BMI,
WC, and insulin resistance markers in the sample used in this
study confirms the important role of this non-invasive tool in
the identification of NAFLD on hypopituitarism patients. This
represents an independent predictor of CVD (22, 23). This
finding may be an alert for screening clinical features used to
detect early risk of developing metabolic syndrome. Considering
criteria based on insulin resistance, and supported by waist
circumference data, MetS prevalence ranges between 10 and
84% worldwide, depending on the geographic region, urban or
rural environment, individual demographic characteristics of the
population studied (gender, age, racial, and ethnic origin), and
the criteria used to define MetS (24).







BMI (kg/m²) 24.03 ± 6.0 24.43 ± 5.0 0.360
WC (cm) 89.4 ± 14.1 87.0 ± 12.3 0.034
IGF-I (ng/ml) 50.0 ± 45.0 169.0 ± 64.5 0.002
Glucose (mg/dl) 79.1 ± 8.3 85.5 ± 6.2 0.004
Insulin (µUI/ml) 5.1 ± 12.1 7.2 ± 11.3 0.013
HOMA IR 1.1 ± 2.6 1.5 ± 2.6 0.006
HbA1c (%) 5.2 ± 0.2 5.2 ± 0.2 0.331
Total cholesterol (mg/dl) 185.8 ± 30.2 186.8 ± 41.2 0.919
HDL-cholesterol (mg/dl) 47.7 ± 11.6 42.8 ± 8.1 0.059
LDL-cholesterol (mg/dl) 110.0 ± 27.0 99.2 ± 25.3 0.251
Triglycerides (mg/dl) 99.0 ± 102.0 139.0 ± 276.0 0.064
AST (U/L) 23.0 ± 8.0 23.0 ± 6.0 0.753
ALT (U/L) 21.0 ± 13.0 16.0 ± 18.0 0.937
GGT (U/L) 17.0 ± 22.0 19.0 ± 23.0 0.700
CAP (dB/m) 217.0 ± 108.0 245.0 ± 98.0 0.972
LSM (kPa) 5.07 ± 1.62 4.62 ± 1.25 0.181
LBM (%) 60.4 ± 8.5 64.7 ± 10.7 0.004
FBM (%) 34.7 ± 8.8 32.0 ± 9.8 0.008
TFM (%) 43.9 ± 5.9 41.7 ± 15.5 0.039
waist/hip ratio 1.10 ± 0.18 1.06 ± 0.13 0.021
BMI, body mass index; WC, waist circumference; IGF-1, insulin growth factor type 1;
HOMA IR, insulin resistance index; HbA1c, glycated hemoglobin; HDL, high density
lipoprotein; LDL, low density lipoprotein; AST, aspartate aminotransferase; ALT- alanine
aminotransferase; GGT, gamma glutamyltranspeptidase; CAP, controlled attenuation
parameter; LSM, liver stiffness measurement; LBM, lean body mass; FBM, fat body mass;
TFM, truncal fat mass.
At baseline, BMI was higher in adult-onset GH deficiency, but
both groups presented a high percentage of fat mass, suggesting
that there is a negative repercussion of GH deficiency in body
composition (25). Greater alteration of insulin resistance clinical
profiles, such as BMI, WC, waist/hip ratio, HOMA IR, and
insulin, was observed in the group of patients with AO-GHD
compared to the CO-GHD group. As the interval (years) without
rhGH replacement therapy was similar between the groups,
the differences found on clinical parameters may be related
to genetic predisposition and to exposure to general factors
such as eating behaviors, dietary factors contributing to insulin
resistance, nutrient availability, and reduced or absent physical
activity (26–28).
Furthermore, aging is truly important as an insulin resistance
combined factor related to changes in body composition, insulin
activity suppression by substrates such as free fatty acids (FFAs),
and likely resistance to leptin (29–31). Thereby, as discussed by
other authors, CO-GHD patients are more prone to accumulated
metabolic risks because they have a higher time forward to
hormonal deficiency exposure (32).
Moderated hypercholesterolemia due to an increase in low-
density lipoprotein (LDL) cholesterol has been reported in
patients with GHD (25). These data were not observed in
the studied sample and could be explained in part by the
replacement of rhGH in the group of patients with CO-GHD
Frontiers in Endocrinology | www.frontiersin.org 6 June 2019 | Volume 10 | Article 364
Carvalho-Furtado et al. CAP and Steatosis in AGHD
TABLE 5 | Metabolic changes in the intervention group after 6 months of rhGH replacement therapy according to hepatic steatosis measured by CAP.
HEPÁTIC STEATOSIS
NO (<248 dB/m) YES (≥248 dB/m)
Baseline (n = 8) After 6 months
(n = 8)
P-value Baseline (n = 5) After 6 months
(n = 5)
P-value
Gender (M/F) 5/3 3/2
Corticotherapy (Y/N) 7/1 3/2
rhGH dose (mg) 0.68 ± 0.2 0.48 ± 0.2
BMI (kg/m²) 21.7 ± 5.5 22.4 ± 4.2 0.296 27.8 ± 4.9 27.7.0 ± 4.65 0.704
WC (cm) 84.4 ± 13.3 83.0 ± 11.4 0.390 97.4.0 ± 12.4 93.4 ± 11.9 < 0.001
IGF-I (ng/ml) 43.5 ± 13.6 158.1 ± 38.5 < 0.001 87.6 ± 38.7 182.1 ± 40.8 0.005
Glucose (mg/dl) 76.6 ± 7.2 82.7 ± 4.3 0.058 83.2 ± 9.2 89.8 ± 6.6 0.039
Insulin (µUI/ml) 5.6 ± 5.3 7.5 ± 2.7 0.147 11.6 ± 5.5 18.0 ± 9.0 0.024
HOMA IR 1.05 ± 1.1 1.5 ± 0.6 0.073 2.4 ± 1.3 4.1 ± 2.2 0.026
HbA1c (%) 5.1 ± 0.25 5.2 ± 0.18 0.096 5.2 ± 0.1 5.3 ± 0.2 0.056
Total cholesterol (mg/dl) 179.5 ± 26.0 170.1 ± 35.8 0.474 195.8 ± 36.8 213.4 ± 37.5 0.262
HDL-cholesterol (mg/dl) 49.6 ± 11.8 45.6 ± 6.6 0.305 44.6 ± 11.8 38.2 ± 9.0 0.060
LDL-cholesterol (mg/dl) 107.1 ± 28.8 96.0 ± 21.0 0.184 114.5 ± 26.0 104.4 ± 33.2 0.662
Triglycerides (mg/dl) 117.4 ± 59.8 150.5 ± 126.3 0.426 191.8 ± 177.2 367.0 ± 317.3 0.085
AST (U/L) 27.0 ± 8.4 24.7 ± 6.6 0.526 21.0 ± 4.2 26.2 ± 8.8 0.308
ALT (U/L) 20.1 ± 10.1 18.5 ± 9.8 0.756 26.0 ± 9.6 31.8 ± 17.6 0.502
GGT (U/L) 18.6 ± 11.0 15.9 ± 8.3 0.339 55.4 ± 62.3 69.8 ± 70.7 0.433
LSM (kPa) 5.3 ± 1.9 4.7 ± 1.5 0.294 4.7 ± 1.02 4.4 ± 0.9 0.354
CAP (dB/m) 194.4 ± 24.3 215.4 ± 51.3 0.267 297.2 ± 32.3 276.4 ± 27.8 0.082
LBM (%) 62.0 ± 10.2 67.4 ± 12.9 0.016 57.72 ± 4.5 60.2 ± 4.0 0.152
FBM (%) 32.5 ± 10.5 28.6 ± 11.2 0.012 38.2 ± 3.5 37.5 ± 3.2 0.234
TFM (%) 43.0 ± 11.7 32.8 ± 12.0 0.043 44.1 ± 1.6 48.4 ± 11.2 0.440
waist/hip ratio 1.05 ± 0.11 0.98 ± 0.10 0.060 1.14 ± 1.07 1.11 ± 0.07 0.274
M/F, male/female; N/Y, yes/no; rhGH, human growth hormone; BMI, body mass index; WC, waist circumference; IGF-1, insulin growth factor type 1; HOMA IR, insulin resistance
index; HbA1c, glycated hemoglobin; HDL, high density lipoprotein; LDL, low density lipoprotein; AST, aspartate aminotransferase; ALT- alanine aminotransferase; GGT, gamma
glutamyltranspeptidase; LSM, liver stiffness measurement; CAP, controlled attenuation parameter; LBM: lean body mass; FBM, fat body mass; TFM, truncal fat mass.
during childhood. The use of statins (data not shown) and the
extreme individual lipid variations (mainly in the concentration
of triglycerides) also contributed to these findings.
At baseline, the IGF1 showed no significant difference
between groups, contrary to the literature reports (33–35), and
may be related to the severity of pituitary deficiency present in
both groups of MPHD patients.
A general overview of pathophysiological mechanisms that
lead to insulin resistance in GHD patients gives them a higher
risk of NAFLD development (23). The evaluation of hepatic
steatosis by CAP of the considered sample confirmed the
presence of risk factors such as for overweight, increased WC,
and increased insulin levels as components of MetS hepatic
manifestation (36, 37).
Liver biopsy remains the gold standard for the diagnosis of
steatohepatitis and staging of fibrosis in patients with NAFLD,
which is the strongest predictor for disease-specific mortality.
Nevertheless, liver biopsy is invasive and associated with a
low rate of complications such as pain and bleeding and
restrains liver disease monitoring (14, 38). The current European
Association for the Study of the Liver (EASL) guidelines for
the management of NAFLD recommend TE as a non-invasive
method for liver fibrosis assessment and monitoring (39). A
recent study confirmed that transient elastography has the best
non-invasive performance to evaluate liver fibrosis in NAFLD
(19). In our series, no fibrosis changes were suggested by LSM,
so a liver biopsy was not indicated in this cohort. In MPHD
hypopituitary patients, complication and risks have increased
such as hemorrhage, related to the use of corticosteroids,
estrogens, and testosterone (11).
Patient with liver steatosis could also present a higher
concentration of alanine aminotransferase with or without
steatohepatitis. Although CAP measures reached statically
significant transaminase differences, the absolute values were not
higher than the reference values. These findings are in agreement
with reports of normal transaminase in more than 70% of the
patients with NAFLD (40).
Considering the metabolic findings hold up the development
of NAFLD in the AO-GHD group, we observed a prevalence of
severe steatosis on CO-GHD patients, highlighting the need for
early diagnosis and intervention in this GHD group.
Intervention with rhGH in a selected group of patients with
GHD resulted in a statistically significant effect on the corporal
composition profiles, with an increase of lean mass and decrease
of fat mass, truncal fat mass, and waist/hip ratio. This only
occurred within the group of patients without hepatic steatosis
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at baseline. The lack of improvement in corporal composition
in patients with steatotic liver may suggest a reduction of GH
signaling in this condition, as recently described by Rufinatscha
(41). On the other hand, this hypothesis could also suggest
that the non-improvement of liver steatosis degree measured by
CAP in our study could be related to reduced GH action on
hepatic enzymes important to lipidic metabolism. This finding
is in agreement with reports of non-improvement of steatosis
with rhGH on GHD patients measured by other steatosis
identification methods (37). This is in disagreement with the
important role of GH and IGF-1 in the liver and the NAFLD
improvement (42) and could be related to the short period of
follow up in our study.
The worsening of the insulin resistance observed on the
intervention group associated with steatosis by CAP could be
transitory and followed by recovery of insulin sensitivity after
therapy suspension, as has already been established (43, 44). At
the same time, it was recently reported that the GH signaling
in the liver could be diminished in patients with NAFLD,
leading to hepatic insulin sensitivity and metabolic activity
deterioration (41).
In conclusion, we have demonstrated the importance of
CAP as a non-invasive tool in liver steatosis identification
of hypopituitary patients. This method may be an important
indicator of the severity of metabolic disorders in MPHD
patients. In our study, no liver health modification in LSM at
baseline and after 6 months of rhGH replacement was found.
Further studies can help to establish the potential repercussion
of growth hormone replacement therapy on liver steatosis.
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